Under Diagnosis and Over Diagnosis of Prostate Cancer

Journal of Urology

Volumn 178, Issue 1, 2007, Pages 88-92

  Graif, Theresa ^a   Loeb, Stacy ^b   Roehl, Kimberly A ^c   Gashti, Sara N ^a   Griffin, Christopher ^a   Yu, Xiaoying ^a   Catalona, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

diagnosis; mass screening; prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

AGED; HUMANS; LYMPHATIC METASTASIS; MALE; MASS SCREENING; NEOPLASM INVASIVENESS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SEMINAL VESICLES;

EID: 34250338507     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.03.017     Document Type: Article

References (19)

1. American Cancer Society. Cancer Facts and Figures (2007). http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf Available at http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf. Accessed January 28, 2007
2. Surveillance, Epidemiology and End Results (SEER) Program. SEER*Stat Database: Mortality-All COD, Public-Use With State, Total U. S. (1969-2003). National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch, released April 2006. Available at www.seer.cancer.gov. Underlying mortality data provided by National Center for Health Statistics. Available at www.cdc.gov/nchs. Accessed October 18, 2006.
3. Draisma G., Boer R., Otto S.J., vanderCruijsen I.W., Damhuis R.A.M., Schroder F.H., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. JNCI 95 (2003) 868
4. Talcott J.A. What patients should be told before agreeing to a blood test that could change their lives. Urology 61 (2003) 7
5. Hoffman R.M. Viewpoint: limiting prostate cancer screening. Ann Intern Med 144 (2006) 438
6. Smith D.S., and Catalona W.J. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 152 (1994) 1732
7. Ohori M., Wheeler T.M., Dunn J.K., Stamey T.A., and Scardino P.T. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 152 (1994) 1714
8. Draisma G., and DeKoning H.J. MISCAN: estimating lead-time and over-detection by simulation. BJU Int, suppl. 92 (2003) 106
9. Etzioni R., Penson D.F., Legler J.M., di Tommaso D., Boer R., Gann P.H., et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U S prostate cancer incidence trends. JNCI 94 (2002) 981
10. McGregor M., Hanley J.A., Boivin J.F., and McLean R.G. Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 159 (1998) 1368
11. Epstein J.I., Walsh P.C., Carmichael M., and Brendler C.B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 (1994) 368
12. Postma R. Population Based Screening for Prostate Cancer: Prognostic Findings of Two Subsequent Screening Rounds (2006), Erasmus University, Rotterdam
13. Wong Y.N., Mitra N., Hudes G., Localio R., Schwartz J.S., Wan F., et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 296 (2006) 2683
14. Karakiewicz P.I., Eastham J.A., Graefen M., Cagiannos I., Stricker P.D., Klein E., et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology 66 (2005) 1245
15. Han M., Partin A.W., Chan D.Y., and Walsh P.C. An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol 171 (2004) 23
16. Wieder J.A., and Soloway M.S. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol 160 (1998) 299
17. Roehl K.A., Eggener S.E., Loeb S., Smith N.D., Antenor J.A., and Catalona W.J. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results. Urol Oncol 24 (2006) 465
18. van der Cruijsen-Koeter I.W., Vis A.N., Roobol M.J., Wildhagen M.F., de Koning H.J., van der Kwast T.H., et al. Comparison of screen detected and clinically diagnosed prostate cancer in the European Randomized Study of Screening for Prostate Cancer, Section Rotterdam. J Urol 174 (2005) 121
19. Humphrey P.A., and Vollmer R.T. Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod Pathol 10 (1997) 326